Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12227
Abstract: Dear Editor, The RAS gene is one of the most frequent oncogenes in human cancers, with significantly different mutation frequencies. The RAS family contains three isoforms: KRAS, HRAS and NRAS, with the KRAS mutations being… read more here.
Keywords: chemotherapy; treatment; patients kras; non small ... See more keywords
Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2016.08.005
Abstract: Micro‐Abstract The nonrandomized phase 2 APEC trial investigated first‐line once‐every‐2‐weeks cetuximab plus chemotherapy (investigator's choice of FOLFOX or FOLFIRI) studied patients with KRAS/RAS wild‐type metastatic colorectal cancer. We observed an activity and safety profile similar… read more here.
Keywords: folfox folfiri; weeks cetuximab; line; first line ... See more keywords
Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.advprecmed20-12
Abstract: Background: KRAS is the most common oncogene in lung cancers, but despite decades of intense research, there are no FDA-approved drugs targeting these cancers. Recent recognition that KRAS G12C harbors a binding pocket near the… read more here.
Keywords: ctdna; non g12c; patients kras; cancer ... See more keywords